Publications by authors named "Neil O'Brien"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

500

Total Likes

15

Extended Reach

877

Social Features

3
D
Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers.
Neil A O'Brien, Martina S J McDermott, Jun Zhang, Ke Wei Gong, Ming Lu

Mol Cancer Ther· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brain PET and SPECT imaging and quantification: a survey of the current status in the UK.
Sofia K Michopoulou, John C Dickson, Glen G Gardner, Thomas R Gee, Andrew J Fenwick, Neil O'Brien

Nucl Med Commun· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The PMA phorbol ester tumor promoter increases canonical Wnt signaling via macropinocytosis.
Nydia Tejeda-Munoz, Yagmur Azbazdar, Julia Monka, Grace Binder, Alex Dayrit, Neil O'Brien

Elife· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
Martina S J McDermott, Brigid C Browne, Neil T Conlon, Neil A O'Brien, Dennis J Slamon

Mol Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The PMA Phorbol Ester Tumor Promoter Increases Canonical Wnt Signaling Via Macropinocytosis.
Nydia Tejeda-Muñoz, Yagmur Azbazdar, Julia Monka, Grace Binder, Alex Dayrit, Neil O'Brien

bioRxiv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the IL1β Pathway for Cancer Immunotherapy Remodels the Tumor Microenvironment and Enhances Antitumor Immune Responses.
Rohan Diwanji, Neil A O'Brien, Jiyoung E Choi, Beverly Nguyen, Tyler Laszewski

Cancer Immunol Res· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy.
Zev A Wainberg, Arun S Singh, Gottfried E Konecny, Kelly E McCann, J Randolph Hecht, Neil O'Brien

Clin Cancer Res· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib.
Seth A Wander, Neil O'Brien, Lacey M Litchfield, Declan O'Dea, Claudia Morato Guimaraes

Oncologist· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies.
Neil A O'Brien, Holly K T Huang, Martina S J McDermott, Athena M Madrid, Tong Luo

Mol Cancer Ther· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting Forefoot-Orthosis Interactions in Rheumatoid Arthritis Using Computational Modelling.
Emily S Kelly, Peter R Worsley, Catherine J Bowen, Lindsey S Cherry, Bethany E Keenan, Neil O'Brien

Front Bioeng Biotechnol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells.
Christen Dillard, Meagan Kiyohara, Vei Mah, Sean P McDermott, Dana Bazzoun, Neil A O'Brien

Mol Cancer Ther· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
Neil A O'Brien, Martina S J McDermott, Dylan Conklin, Tong Luo, Raul Ayala

Breast Cancer Res· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
Alexandra Canonici, Laura Ivers, Neil T Conlon, Kasper Pedersen, Nicola Gaynor, Neil A O'Brien

Invest New Drugs· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutralization of BCL-2/X Enhances the Cytotoxicity of T-DM1 .
Jason J Zoeller, Aleksandr Vagodny, Krishan Taneja, Benjamin Y Tan, Neil O'Brien

Mol Cancer Ther· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role for polo-like kinase 4 in mediation of cytokinesis.
Michael F Press, Bin Xie, Simon Davenport, Yu Zhou, Roberta Guzman, Neil O'Brien

Proc Natl Acad Sci U S A· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells.
Martina S J McDermott, Neil Conlon, Brigid C Browne, Adam Szabo, Naoise C Synnott, Neil A O'Brien

Cancers (Basel)· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
Alex J Eustace, Neil T Conlon, Martina S J McDermott, Brigid C Browne, Patrick O'Leary, Neil A O'Brien

BMC Cancer· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.
Alexandra Canonici, Zulfiqar Qadir, Neil T Conlon, Denis M Collins, Neil A O'Brien

Invest New Drugs· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MKAD-21 Suppresses the Oncogenic Activity of the miR-21/PPP2R2A/ERK Molecular Network in Bladder Cancer.
Marina Koutsioumpa, Hsiao-Wang Chen, Neil O'Brien, Filippos Koinis, Swapna Mahurkar-Joshi

Mol Cancer Ther· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer.
Neil O'Brien, Dylan Conklin, Richard Beckmann, Tong Luo, Kevin Chau

Mol Cancer Ther· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells.
Martina S J McDermott, Alexandra Canonici, Laura Ivers, Brigid C Browne, Stephen F Madden, Neil A O'Brien

Int J Oncol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent Advances in X-ray Cone-beam Computed Laminography.
Neil S O'Brien, Richard P Boardman, Ian Sinclair, Thomas Blumensath

J Xray Sci Technol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response.
Sara A Hurvitz, Ondrej Kalous, Dylan Conklin, Amrita J Desai, Judy Dering, Neil A O'Brien

Breast Cancer Res Treat· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
Martina Sj McDermott, Brigid C Browne, Neil T Conlon, Neil A O'Brien, Dennis J Slamon

Mol Cancer· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis